Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This paper introduces VHR-PRO_IT (Very High-Resolution PROjections for ITaly), an open access hourly climate projection with a resolution of ≃2.2 km (i.e., Convection Permitting Scale) up to 2050, covering the Italian peninsula and some neighbouring areas. VHR-PRO_IT is produced within the Highlander project ( https://highlanderproject.eu/ ) by dynamically downscaling the Italy8km-CM climate projection (spatial resolution ≃8 km; output frequency = 6 h; driven CMIP5 GCM = CMCC-CM) with the Regional Climate Model COSMO-CLM under the IPCC RCP4.5 and RCP8.5 scenarios. It covers the 60-year period 1989-2050. VHR-PRO_IT is intended for research purposes in the field of climate studies. For example, it may be included in the ongoing activities to clarify the added value of running climate simulation at the convection-permitting scale.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133389 | PMC |
| http://dx.doi.org/10.1038/s41597-023-02144-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Supplementary Material for Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data from Nine Countries.
Clin Gastroenterol Hepatol
September 2025
The Global NASH/MASH Council, Washington, DC, United States; Gastroenterology Section, Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Liver, Digestive, and Lifestyle Health Research Section, and Organ Transplant Center of Excellence, King Faisal Sp
Background And Aim: Although the clinical burden of MASH is well known, its economic burden is less well described. We estimated MASH's economic burden in several regions of the world including the US, Germany, Spain, France, Italy, and United Kingdom (UK), Japan, Saudi Arabia, and Brazil over the next two decades.
Methods: A one-year cycle Markov model projected MASH progression from 2021 to 2040, incorporating 2020 prevalent cases and annual incident cases (2021-2040).
Comment to: "Comparison of Same Versus Different Projection Implants in Asymmetric Tuberous Breasts: Long-Term Outcomes and Patient Satisfaction Analysis".
Aesthetic Plast Surg
September 2025
Plastic and Reconstructive Microsurgery, Careggi University Hospital, Viale Giacomo Matteotti 42, 50132, Florence, Italy.
Global burden of anxiety, depression, self-harm (1990-2021) and the impact of COVID-19 pandemic.
J Affect Disord
September 2025
Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea; Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; D
Background: Major depressive disorder (MDD), anxiety disorders, and self-harm are substantial contributors to the global disease burden, exacerbated by the COVID-19 pandemic.
Methods: We used Global Burden of Diseases Study (GBD) 2021 to estimate global, regional, and national prevalence, mortality, and disability-adjusted life years (DALYs) for MDD, anxiety disorders, and self-harm from 1990 to 2021. Annual percentage changes were calculated for pre-pandemic (1990-2019) and pandemic (2019-2021) periods.
Many plants naturalized as aliens abroad have also become more common within their native regions.
Nat Commun
September 2025
Ecology, Department of Biology, University of Konstanz, Konstanz, Germany.
Due to anthropogenic pressure some species have declined whereas others have increased within their native ranges. Simultaneously, many species introduced by humans have established self-sustaining populations elsewhere (i.e.
View Article and Find Full Text PDFEarly Diagnosis and Timely Terlipressin in Hepatorenal Syndrome Improves Projected Outcomes and Lowers Cost.
Clinicoecon Outcomes Res
August 2025
Mallinckrodt Pharmaceuticals, Bridgewater, NJ, USA.
Introduction: Terlipressin is the only Food and Drug Administration-approved medication for adults with hepatorenal syndrome-acute kidney injury (HRS-AKI) with rapid reduction in kidney function. Treatment with terlipressin, particularly in patients with lower serum creatinine (SCr) at diagnosis, improves outcomes. Despite evidence suggesting that treating HRS-AKI at lower SCr thresholds may improve clinical outcomes, the impact on healthcare resource utilization (HCRU) and medical costs of an earlier intervention strategy remains unquantified.
View Article and Find Full Text PDF